MIV in polymer-free DES (drug-eluting stent) trial:
This article was originally published in Clinica
As part of its bid to bring to market technology that it claims could lead to improved drug-eluting stents (DESs), MIV Therapeutics has performed the first-in-man implant of its polymer-free DES. The MIVT Pilot Trial, which is being conducted in Brazil, will evaluate the safety and efficacy of the device in patients with single de novo lesions in their native coronary arteries. The product combines the company's GenX coronary stent with one of its hydroxyapatite polymer-free drug-eluting systems that is 700 nanometers thin. The Atlanta, Georgia firm believes its new class of polymer-free DESs could provide patients with superior outcomes.